Skip to main content
. 2020 Mar 31;23(4):101028. doi: 10.1016/j.isci.2020.101028

Figure 4.

Figure 4

Oncogenic BRAF Enhances eIF4B Phosphorylation for ATF4 Induction

(A) Immunoblot analysis of A375 and G-361 cells treated with vemurafenib (VEM, 10 μM) for the indicated times.

(B) Immunoblot analysis of the melanoma cell lines with BRAF knockdown.

(C) Immunoblot analysis of HEK293T and A375 cells with overexpression of wild-type BRAF or mutant BRAF.

(D and E) Immunoblot analysis of A375 and G-361 cells with EIF4B knockdown and treatment with vemurafenib (10 μM) or dabrafenib (DAB, 1 μM) (D) or with L-histidinol (HIS, 2 mM) (E) for 4 h.

(F and G) Immunoblot analysis of A375 and G-361 cells with EIF4A1 knockdown and treated with vemurafenib (10 μM) (F) or with L-histidinol (2 mM), tunicamycin (TM, 1 μg/mL), or thapsigargin (TG, 0.3 μM) (G) for 4 h.

See also Figure S4.